HDAC inhibitors have been shown to decrease the production of pro-inflammatory cytokines, such as TNF-α and IL-6, and to increase the activity of regulatory T cells, which can help to suppress the immune response in RA [117,118]. Here, HDAC9 is linked to rheumatoid arthritis.